NYU Langone Medical Center
out of 16
Post on 12-Nov-2014
DESCRIPTIONNYU Langone Medical Center*References*Blackburn G. Effect of degree of weight loss on health benefit...
<ul><li> 1. NYU Langone Medical Center NYU Langone Medical Center * References *Blackburn G. Effect of degree of weight loss on health benefits.Obes Res.1995;3(suppl 2):211S216S. *Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II.Ann Intern Med.2001;134:1-11. *Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study.Ann Intern Med.1992;116:535-539. *Goldstein DJ. Beneficial health effects of modest weight loss.Int J Obes.1992;16:397-415. *Solomon CG, Manson JE. Obesity and mortality: a review of the epidemiologic data.Am J Clin Nutr.1997;66(suppl 4):1044S-1050S. *Moore LL, Visioni AJ, Wilson PW, et al. Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus?Epidemiology.2000;11:269-273. *Kaats GR, Blum K, Fisher JA, et al. Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study.Curr Ther Res.1996;57:747765. *Kaats GR, Blum K, Pullin D, et al. A randomized, double-masked, placebo-controlled study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study.Curr Ther Res.1998;59:379-388. *Grant KE, Chandler RM, Castle AL, et al. Chromium and exercise training: Effect on obese women.Med Sci Sports Exerc.1997;29:992-998. *Trent LK, Thieding-Cancel D. Effects of chromium picolinate on body composition.J Sports Med Phys Fitness.1995;35:273-280. *Clancy SP, Clarkson PM, DeCheke ME, et al. Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players.Int J Sport Nutr.1994;4:142-153. *Hallmark MA, Reynolds TH, DeSouza CA, et al. Effects of chromium and resistive training on muscle strength and body composition.Med Sci Sports Exerc.1996;28:139-144. *Amato P, Morales AJ, Yen SS. Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women.J Gerontol A Biol Sci Med Sci.2000;55:M260-M263. *Lukaski HC, Bolonchuk WW, Siders WA, et al. Chromium supplementation and resistance training: </li> <li> 2. effects on body composition, strength, and trace element status of men.Am J Clin Nutr.1996;63:954964. *Stanko RT, Reynolds HR, Hoyson R, et al. Pyruvate supplementation of a low-cholesterol, low-fat diet: effects on plasma lipid concentrations and body composition in hyperlipidemic patients.Am J Clin Nutr.1994;59:423-427. *Stanko RT, Tietze DL, Arch JE. Body composition, energy utilization, and nitrogen metabolism with a 4.25-MJ/d low-energy diet supplemented with pyruvate.Am J Clin Nutr.1992;56:630-635. *Stanko RT, Arch JE. Inhibition of regain in body weight and fat with addition of 3-carbon compounds to the diet with hyperenergetic refeeding after weight reduction.Int J Obes Relat Metab Disord.1996;20:925-930. *Stanko RT, Tietze DL, Arch JE. Body composition, energy utilization, and nitrogen metabolism with a severely restricted diet supplemented with dihydroxyacetone and pyruvate.Am J Clin Nutr.1992;55:771-772. *Kalman D, Colker CM, Wilets I, et al. The effects of pyruvate supplementation on body composition in overweight individuals.Nutrition.1999;15:337-340. *Ryttig KR, Tellnes G, Haegh L, et al. A dietary fibre supplement and weight maintenance after weight reduction: a randomized, double-blind, placebo-controlled long-term trial.Int J Obes.1989;13:165-171. *Rigaud D, Ryttig KR, Angel LA, et al. Overweight treated with energy restriction and a dietary fibre supplement: a 6-month randomized, double-blind, placebo-controlled trial.Int J Obes.1990;14:763769. *Rossner S, von Zweigbergk D, Ohlin A, et al. Weight reduction with dietary fibre supplements. Results of two double-blind randomized studies.Acta Med Scand.1987;222:83-88. *Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study.Int J Obes.1984;8:289-293. *Reffo GC, Ghirardi PE, Forattani C. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation.Curr Ther Res.1990;47:753-758. *Vido L, Facchin P, Antonello I, et al. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo.Paediatr Paedol.1993;28:133-136. *Schiller RN, Barrager E, Schauss AG, et al. A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals.J Am Nutraceutical Assoc.2001;4:42-49. *Pittler MH, Abbot NC, Harkness EF, et al. Randomized, double-blind trial of chitosan for body weight reduction.Eur J Clin Nutr.1999;53:379-381. *Di Lorenzo C, Williams CM, Hajnal F, et al. Pectin delays gastric emptying and increases satiety in obese subjects.Gastroenterology.1988;95:1211-1215. </li> <li> 3. *Wilmshurst P, Crawley JC. The measurement of gastric transit time in obese subjects using 24Na and the effects of energy content and guar gum on gastric emptying and satiety.Br J Nutr.1980;44:16. *Heini AF, Lara-Castro C, Schneider H, et al. Effect of hydrolyzed guar fiber on fasting and postprandial satiety and satiety hormones: a double-blind, placebo-controlled trial during controlled weight loss.Int J Obes.1998;22:906-909. *Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study.Int J Obes.1984;8:289-293. *Reffo GC, Ghirardi PE, Forattani C. Double-blind evaluation of glucomannan versus placebo in postinfarcted patients after cardiac rehabilitation.Curr Res Ther.1990;47:753-758. *Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial.Diabetes Care.1999;22:913-919. *Ryttig KR, Tellnes G, Haegh L, et al. A dietary fibre supplement and weight maintenance after weight reduction: a randomized, double-blind, placebo-controlled long-term trial.Int J Obes.1989;13:165-171. *Rossner S, von Zweigbergk D, Ohlin A, et al. Weight reduction with dietary fibre supplements. Results of two double-blind randomized studies.Acta Med Scand.1987;222:83-88. *Byerley WF, Judd LL, Reimherr FW, et al. 5-hydroxytryptophan: a review of its antidepressant efficacy and adverse effects.J Clin Psychopharmacol.1987;7:127-137. *Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: Serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine.Psychopathology.1991;24:53-81. *Ceci F, Cangiano C, Cairella M, et al. The effects of 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects.J Neural Transm.1989;76:109-117. *Cangiano C, Ceci F, Cascino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan.Am J Clin Nutr.1992;56:863-867. *Cangiano C, Ceci F, Cairella M, et al. Effects of 5-Hydroxytryptophan on eating behavior and adherence to dietary prescriptions in obese adult subjects.Adv Exp Med Biol.1991;294:591-593. *Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients.Int J Obes Relat Metab Disord.1998;22:648-654. *Chao D, Espeland MA, Farmer D, et al. Effect of voluntary weight loss on bone mineral density in older overweight women.J Am Geriatr Soc.2000;48:753-759. *Davies KM, Heaney RP, Recker RR, et al. Calcium intake and body weight.J Clin Endocrinol Metab.2000;85:4635-4638. </li> <li> 4. *Greenwood MRC, Cleary MP, Gruen R, et al. Effect of hydroxycitrate on development of obesity in the Zucker obese rat.Am J Physiol.1981;240:E72-E78. *Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. Influence ofhydroxycitrate on experimentally induced obesity in the rodent.Am J Clin Nutr.1977;30:767-776. *Sullivan AC, Triscari J, Hamilton JG, et al. Effect ofhydroxycitrate upon the accumulation of lipid in the rat: I. Lipogenesis.Lipids.1974;9:121-128. *Sullivan AC, Triscari J, Hamilton JG, et al. Effect ofhydroxycitrate upon the accumulation of lipid in the rat. II. Appetite.Lipids.1974;9:129-134. *Sergio W. A natural food, malabar tamarind, may be effective in the treatment of obesity.Med Hypotheses.1988;27:39-40. *Lowenstein JM. Effect of hydroxycitrate on fatty acid synthesis by rat liver in vivo.J Biol Chem.1971;246:629-632. *Triscari J, Sullivan AC. Comparative effects of hydroxycitrate and (+)-allo-hydroxycitrate on acetyl CoA carboxylase and fatty acid and cholesterol synthesis in vivo.Lipids.1977;12:357-363. *Cheema-Dhadli S, Harlperin ML, Leznoff CC. Inhibition of enzymes which interact with citrate by hydroxycitrate and 1,2,3,-tricarboxybenzene.Eur J Biochem.1973;38:98-102. *Sullivan AC, Hamilton JG, Miller ON, et al. Inhibition of lipogenesis in rat liver byhydroxycitrate.Arch Biochem Biophys.1972;150:183-190. *Heymsfield SB, Allison DB, Vasselli JR, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial.JAMA.1998;280:1596-1600. *Kriketos AD, Thompson HR, Greene H, et al. Hydroxycitric acid does not affect energy expenditure and substrate oxidation in adult males in a post-absorptive state.Int J Obes Relat Metab Disord.1999;23:867-873. *Mattes RD, Bormann L. Effects of hydroxycitric acid on appetitive variables.Physiol Behav.2000;71:87-94. *Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial.Int J Obes Relat Metab Disord.1992;16:269-277. *Molnar D, Torok K, Erhardt E, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind, placebo-controlled pilot study in adolescents.Int J Obes Relat Metab Disord.2000;24:1573-1578. *Breum L, Pedersen JK, Aglstrom, et al. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.Int Obes Relat Metab Disord.1994;18:99-103. *Boozer CN, Nasser JA, Heymsfield SB, et al. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial.Int J Obes Relat Metab Disord.2001;25:316-324. </li> <li> 5. *Norregaard J, Jorgensen S, Mikkelsen KL, et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain.Clin Pharmacol Ther.1996;60:679-686. *Astrup A, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double-blind trial.Int J Obes Relat Metab Disord.1992;16:269-277. *Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists.Obes Res.1995;3:537S-540S. *Naylor GJ, et al. A double blind placebo controlled trial of ascorbic acid in obesity.IRCS J Med Sci.1982;10:25-28. *Naylor GJ, Grant L, Smith C. A double blind placebo controlled trial of ascorbic acid in obesity.Nutr Health.1985;4:25-28. *Haslett C, Douglas JG, Chalmers SR, et al. A double-blind evaluation of evening primrose oil as an antiobesity agent.Int J Obes.1983;7:549-553. *Garcia CM, Carter J, Chou A. Gamma linolenic acid causes weight loss and lower blood pressure in overweight patients with family history of obesity.Swed J Biol Med.1986;4:8-11. *Thom E. A pilot study with the aim of studying the efficacy and tolerability of CLA (Tonalin) on the body composition in humans [unpublished]. July 1997. *West D. Reduced body fat with conjugated linoleic acid feeding in the mouse [abstract].FASEB J.1997;11:A599. *Ferreira M, Kreider R, Wilson M, et al. Effects of conjugated linoleic acid (CLA) supplementation during resistance training on body composition and strength [abstract].J Strength Cond Res.1997;11:280. *Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic acid reduces body fat mass in overweight and obese humans.J Nutr.2000;130:2943-2948. *Nagao T, Watanabe H, Goto N, et al. Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men in a double-blind controlled trial.J Nutr.2000;130:792-797. *Becker EW, Jakober B, Luft D, et al. Clinical and biochemical evaluations of the alga Spirulina with regard to its application in the treatment of obesity. A double-blind cross-over study.Nutr Rep Int.1986;33:565-574. *Hoeger WWK, Harris C, Long EM, et al. Four-week supplementation with a natural dietary compound produces favorable changes in body composition.Adv Ther.1998;15:305-314. *Colker CM, Kalman DS, Torina GC, et al. Effects of Citrus aurantium extract, caffeine, and St. John's wort on body fat loss, lipid levels, and mood states in overweight healthy adults.Curr Ther Res.1999;60:145-153. *Dulloo AG, Seydoux J, Girardier L, et al. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity.Int J Obes Relat Metab Disord.2000;24:252- </li> <li> 6. 258. *Antonio J, Colker CM, Torina GC, et al. Effects of a standardized guggulsterone phosphate supplement on body composition in overweight adults: A pilot study.Curr Ther Res.1999;60:220-227. *Villani RG, Gannon J, Self M, et al. L-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women.Int J Sport Nutr Exerc Metab.2000;10:199-207. *Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, et al. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids, and insulin resistance.Metabolism.1996;45:1011-1015. *Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.Diabetes.1997;46:1786-1791. *Dibling D, Zemel MB. Chromium picolinate antagonized the lipogenic and antilipolytic effects of insulin in human adipocytes [abstract].FASEB J.1998;12:A505. *Cheuvront SN. The zone diet and athletic performance.Sports Med.1999;27:213-228. *Coulston AM, Liu GC, Reaven GM. Plasma glucose, insulin and lipid responses to high-carbohydrate low-fat diets in normal humans.Metabolism.1983;32:52-56. *Lefebvre PJ, Luyckx AS. Effect of insulin on glucagon enhanced lipolysis in vitro...</li></ul>
View more >
Ed Berkovitz NYU Langone Medical Center - Ernst & Young FILE/... · Ed Berkovitz NYU Langone Medical Center At NYU Langone Medical Center, Ed Berkovitz serves as the Director of Tax Reporting and Compliance, is a
NYU Hospital for Joint Diseases NYU Langone Medical Center Fourth Annual Clinical Research Methodology Course Co-Sponsored by NYU Post-Graduate Medical.
NYU Langone Bellevue Hospital Center Emergency ?· Damilola Idowu Brown Sumanth Kaja Weill Cornell Janelle…
Good Vibrations : Management of Deep Brain Stimulation for ET and PD Michael Pourfar, MD Co-Director Center for Neuromodulation NYU Langone Medical Center.
Microsoft Word - Dermpath Fellowship ?? Web viewMicrosoft Word - Dermpath Fellowship Last modified by: admin Company: NYU Langone Medical Center ...
Hospital-Acquired VTE: What We Have Learned Martha J. Radford, MD Chief Quality Officer NYU Langone Medical Center September 2009.
Department of raDiology - NYU Langone Medical Center OF RADIOLOGY | 2012 Quality Report | 3 ver the…
Prevention Research Center - NYU Langone Health ?· CEED/PRC Staff; 5) Conference Morning ... Prevention…
In Case of Emergency - NYU Langone Medical Center Case of Emergency . . . Joshua Bright newsviews SEPTEMBER/OCTOBER 2014 A PUBLICATION FOR THE NYU LANGONE MEDICAL CENTER COMMUNITY Introducing the New Ronald O. ...
RUSK REHABILITATION - NYU Langone Health Predoctoral Internship Program in neurorehabilitation at Rusk Rehabilitation, New York University Langone Medical Center (NYULMC) is an APA accredited program.